IRIS
LAURIA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.175
EU - Europa 4.723
AS - Asia 3.101
SA - Sud America 618
AF - Africa 160
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 16.785
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.089
CN - Cina 1.196
GB - Regno Unito 990
RU - Federazione Russa 979
SG - Singapore 862
IE - Irlanda 756
UA - Ucraina 513
BR - Brasile 509
FR - Francia 374
SE - Svezia 371
VN - Vietnam 310
DE - Germania 263
HK - Hong Kong 258
IT - Italia 222
KR - Corea 158
FI - Finlandia 138
ZA - Sudafrica 88
BD - Bangladesh 75
IN - India 57
CA - Canada 45
AR - Argentina 36
IQ - Iraq 27
NG - Nigeria 21
TR - Turchia 21
MX - Messico 19
ID - Indonesia 18
JP - Giappone 18
EC - Ecuador 17
VE - Venezuela 17
ES - Italia 16
NL - Olanda 16
BE - Belgio 14
CO - Colombia 14
CZ - Repubblica Ceca 14
PK - Pakistan 13
PL - Polonia 13
UZ - Uzbekistan 13
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
CL - Cile 8
EG - Egitto 8
AT - Austria 7
LT - Lituania 7
MY - Malesia 7
CI - Costa d'Avorio 6
JO - Giordania 6
KE - Kenya 6
MA - Marocco 6
NP - Nepal 6
PA - Panama 6
PY - Paraguay 6
SA - Arabia Saudita 6
AU - Australia 5
ET - Etiopia 5
HN - Honduras 5
HR - Croazia 5
PE - Perù 5
SN - Senegal 5
TH - Thailandia 5
EE - Estonia 4
IL - Israele 4
UY - Uruguay 4
AL - Albania 3
GR - Grecia 3
IR - Iran 3
JM - Giamaica 3
KG - Kirghizistan 3
KH - Cambogia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
GE - Georgia 2
LB - Libano 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
FJ - Figi 1
GA - Gabon 1
GM - Gambi 1
GT - Guatemala 1
GY - Guiana 1
HT - Haiti 1
KW - Kuwait 1
KZ - Kazakistan 1
Totale 16.773
Salva come PNG Salva come JPEG
Città #
Fairfield 1.164
Southend 876
Dallas 818
Dublin 753
Ashburn 637
Woodbridge 557
Seattle 469
Singapore 467
Jacksonville 425
Houston 419
Wilmington 417
Santa Clara 389
Cambridge 381
Chandler 358
Beijing 308
Moscow 292
Hong Kong 251
San Jose 198
Ann Arbor 195
Hefei 179
Princeton 163
Seoul 156
Nanjing 154
Ho Chi Minh City 114
The Dalles 94
Los Angeles 89
Siena 79
Lauterbourg 78
Johannesburg 77
Hanoi 61
São Paulo 55
Buffalo 52
Nanchang 51
San Diego 49
Boardman 47
Council Bluffs 45
Helsinki 44
New York 42
San Mateo 34
Shenyang 32
Tianjin 29
Munich 28
Orem 28
San Francisco 27
Shanghai 26
Frankfurt am Main 24
Hebei 24
London 23
Kunming 22
Abuja 20
Toronto 20
Columbus 19
Da Nang 19
Norwalk 18
Redondo Beach 18
Rio de Janeiro 17
Tokyo 17
Bengaluru 16
Changsha 16
Dearborn 16
Hangzhou 16
Jiaxing 16
Brussels 14
Dong Ket 14
Düsseldorf 13
Falls Church 13
Montreal 13
Ningbo 13
Zhengzhou 13
Baghdad 12
Brno 12
Menlo Park 12
Nuremberg 12
Brasília 11
Chicago 11
Curitiba 11
Denver 11
Haiphong 11
Tashkent 11
Chennai 10
Guayaquil 10
Belo Horizonte 9
Cape Town 9
Guarulhos 9
Turku 9
Washington 9
Brooklyn 8
Izmir 8
Lancaster 8
Lanzhou 8
Phoenix 8
Porto Alegre 8
Warsaw 8
Dhaka 7
Guangzhou 7
Hải Dương 7
Milan 7
Palermo 7
Philadelphia 7
Stockholm 7
Totale 11.905
Salva come PNG Salva come JPEG
Nome #
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 290
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 289
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 288
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 272
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 272
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 267
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 265
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 251
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 248
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 242
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 241
Alternative methods of cladribine administration 239
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 238
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 232
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 229
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 229
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 228
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 226
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 225
Emerging drugs in chronic myelogenous leukaemia 217
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 216
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 216
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 213
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 213
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 212
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 212
Towards the pharmacotherapy of hairy cell leukaemia 208
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 208
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 206
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 202
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 201
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 201
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 201
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 200
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 199
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 198
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 196
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 195
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 194
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 193
Predicting the clinical course of Hodgkin lymphoma 191
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 189
The effects of zoledronic acid on serum lipids in multiple myeloma patients 189
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 189
Bcr-abl peptides for chronic myeloid leukemia. 188
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 186
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 183
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 183
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 179
Reply to “Rituximab activity in CD20-positive multiple myeloma” 177
Typical genomic imbalances in primary MALT lymphoma of the orbit 177
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 176
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia 173
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 171
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 171
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 167
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 166
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 166
Comparison of low-dose versus standard-dose alpha-interferon regimen in the hairy cell leukemia treatment 164
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia 164
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 164
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas 164
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency 162
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch 160
Combination therapies to improve the long-term outcome in hairy cell leukemia 159
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance 155
Case-control study of multidrug resistance phenotype and response to induction treatment includine or not fludarabine in newly diagnosed acute myeloid leukemia patients 154
Vaccinoterapia antitumorale: il modello della leucemia mieloide cronica. 153
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma 153
Hairy cell leukemias (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes 148
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib 148
Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years 144
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients 144
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate 142
CMLVAX100 Peptide Vaccinations induce Peptide Specific "cytotoxic" CD4+ T Cells (CD4+CTLs) in Chronic Myeloid Leukemia Patients: New Insights about Peptide Vaccine-Mediated Antitumor Response 141
Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia 138
Hyperlipidemic myeloma 137
Deletion 9q in a patient with concomitant myelodisplasia and non-Hodgkin lymphoma 133
Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC) 129
Evaluation of Ph+/CD34+ residual cells in chronic myeloid leukemia patients after long lasting treatment with imatinib mesylate 128
Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia 126
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia : a new treatment schedule effective and safer in preventing infective complications 125
Imatinib mesylate in the treatment of c-kit positive acute myeloid leukemia: is the real target? 122
Long-lasting complete remission in patients with hairy cell leukemia trated with 2-CdA: a 5-year survey 118
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype 117
Disseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Entercoccus faecium 115
Low-dose fludarabine and cyclophosohamide in elderly patients with B-cell chronic lymphocytic leukemia refractory in conventional theraphy 115
Imatinib plus CMLVAX100 (P210-derived multipeptide vaccine): induction of complete molecular responses in patients with chronic myeloid leukemia (CML) showing persistent residual disease during treatment with imatinib mesylate 109
Promyelocytic blast crisis of chronic myelogenous leukaemia during imatinib treatment. 108
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study 82
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines 80
null 34
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms 5
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant 5
297. Gozzetti A.,Tozzuoli D., Crupi R., Gentili S., Raspadori D., Fabbri A., Lauria F. A t(20;21) (q2;q22.3) in a patient with chronic myelocytic leukemia in blastic phase. 4
Totale 16.842
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.418
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.418
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202196 0 0 0 0 0 0 0 0 0 0 0 96
2021/2022999 65 143 41 73 39 32 47 38 55 124 101 241
2022/20231.393 105 119 223 191 132 290 23 93 128 18 51 20
2023/2024952 39 14 76 61 18 274 362 4 5 12 5 82
2024/20252.109 54 109 189 101 312 116 34 108 178 88 200 620
2025/20264.764 426 787 626 599 827 193 454 155 197 243 153 104
Totale 16.842